| Autor: |
C.E. Hoffmann |
| Rok vydání: |
1976 |
| Předmět: |
|
| Zdroj: |
Annual Reports in Medicinal Chemistry ISBN: 9780120405114 |
| DOI: |
10.1016/s0065-7743(08)61397-4 |
| Popis: |
Publisher Summary It was observed in recent past that much of the virus chemotherapy research was directed at herpes and other DNA viruses and this includes clinical and laboratory studies on known compounds to ascertain their spectrum of clinical efficacy. Antiviral chemotherapy has left the laboratory and is now established in the clinic with useful agents available. Extensive clinical trials have been carried out with ara-A on a variety of virus infections and by different treatment routes. Topical treatment of herpetic keratitis with 3% ointment was reported effective and a good alternate to IDUR therapy. Genital herpes have proven more refractory and double-blind studies show no difference in activity between topical placebo and topical drug treatment. Parenteral administration of ara-A was reported to be curative and well tolerated in the early treatment of severe disseminated herpes infections in infants and adults. Ara-A was found to be completely ineffective for treatment of variola major infections as shown by a double-blind study in 18 patients. A problem with ara-A is its rapid enzymatic conversion to the less active arahypoxanthine (ara-Hx) by adenosine deaminase. A new enzyme inhibitor (Co-Vidarabine, Co-V) has been reported to potentiate the activity of ara-A in tissue culture. The model systems are useful as guides but clinical trials are required. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
